Scarica l'app Stockscreener
42.49
1.21%
0.51
Dopo l'orario di chiusura:
41.86
-0.63
-1.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors to ... - Caledonian Record
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Corcept - GlobeNewswire
Corcept Therapeutics Incorporated $CORT Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud LawsuitInvestors Encouraged to Contact Kaplan Fox - NewMediaWire
Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK - MSN
Corcept Therapeutics Faces Class Action Lawsuit - National Today
Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics IncorporatedCORT - PR Newswire
Corcept (CORT) Class Action Alleges Misstatements on FDA Data ConcernsHagens Berman - ChartMill
Is Corcept Therapeutics (CORT) Pricing Make Sense After Recent Share Price Volatility? - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
CORCEPT THERAPEUTICS DEADLINE: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
CORT Investors Have Opportunity to Lead Corcept - GlobeNewswire
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
Corcept Presents Latest Data from MOMENTUM Trial at ACC.26 - dicardiology.com
ROSEN Law Firm Encourages Corcept Therapeutics Investors - National Today
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to ... - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept - GlobeNewswire
Deadline Alert: Corcept Therapeutics Incorporated (CORT) - GlobeNewswire
User - The Chronicle-Journal
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ - natlawreview.com
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026 - The Globe and Mail
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire
Corcept Therapeutics Incorporated (CORT) Gains on FDA Approval, But Questions Remain - Yahoo Finance
Corcept Therapeutics Class Action Reminder for Investors - Intellectia AI
Corcept Therapeutics Incorporated Securities Fraud Class - GlobeNewswire
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026 - ACCESS Newswire
CORT INVESTOR UPDATE: Hagens Berman Alerts Corcept - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Bragar Eagel & Squire, P.C. Urges Navan and Corcept - GlobeNewswire
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost M - GuruFocus
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally - FinancialContent
Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT) - The Globe and Mail
CORT Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Corcept Therapeutics Incorporated Securities Lawsuit -- The Gross Law Firm - PR Newswire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated ... - Caledonian Record
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages - GlobeNewswire
April 21, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CORT - GlobeNewswire
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - ChartMill
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud ... - Caledonian Record
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session - MarketScreener
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $73 - Moomoo
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN Counsel Encourages Corcept Therapeutics - National Today
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated ... - Caledonian Record
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - AOL.com
Corcept Therapeutics Incorporated Presents Data From Momentum Trial At American College Of Cardiology Annual Scientific Session - MarketScreener
Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Contact Kaplan Fox - NewMediaWire
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):